New nebulised tobramycin product launched

Vantobra (tobramycin) is the latest product to be added to the range of nebulised antibiotics available to treat chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

Vantobra is available as a preservative-free nebuliser solution in single-use 1.7ml ampoules each containing 170mg tobramycin.

The recommended dose for adults and children aged six years and older is 170mg twice daily administered via the Tolero nebuliser handset provided in the pack. As with other nebulised tobramycin preparations, Vantobra should be administered in alternating 28-day cycles of active treatment and rest period. Treatment should be continued for as long as there is clinical benefit.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases